PID No. : MED110806472 Register On : 24/01/2023 8:41 AM : 423004656 **Collection On** : 24/01/2023 9:18 AM SID No. Age / Sex : 43 Year(s) / Female

: 20/03/2023 2:59 PM

Report On : 24/01/2023 4:53 PM

**Printed On** 

Type : OP

Ref. Dr : MediWheel



Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
<b>HAEMATOLOGY</b>			
Complete Blood Count With - ESR			
Haemoglobin (EDTA Blood/Spectrophotometry)	12.8	g/dL	12.5 - 16.0
Packed Cell Volume(PCV)/Haematocrit (EDTA Blood)	39.8	%	37 - 47
RBC Count (EDTA Blood)	4.58	mill/cu.mm	4.2 - 5.4
Mean Corpuscular Volume(MCV) (EDTA Blood)	87.0	fL	78 - 100
Mean Corpuscular Haemoglobin(MCH) (EDTA Blood)	27.9	pg	27 - 32
Mean Corpuscular Haemoglobin concentration(MCHC) (EDTA Blood)	32.1	g/dL	32 - 36
RDW-CV (EDTA Blood)	15.2	%	11.5 - 16.0
RDW-SD (EDTA Blood)	46.28	fL	39 - 46
Total Leukocyte Count (TC) (EDTA Blood)	7700	cells/cu.mm	4000 - 11000
Neutrophils (EDTA Blood)	70.6	%	40 - 75
Lymphocytes (EDTA Blood)	23.3	%	20 - 45
Eosinophils (EDTA Blood)	1.0	%	01 - 06
Monocytes (EDTA Blood)	4.5	%	01 - 10





 PID No.
 : MED110806472
 Register On
 : 24/01/2023 8:41 AM

 SID No.
 : 423004656
 Collection On
 : 24/01/2023 9:18 AM

 Age / Sex
 : 43 Year(s) / Female
 Report On
 : 24/01/2023 4:53 PM

M

**Printed On** : 20/03/2023 2:59 PM

Ref. Dr : MediWheel

(Citrated Blood)

: OP

Type

Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Basophils	0.6	%	00 - 02
(Blood)  INTERPRETATION: Tests done on Automated Five P	art cell counter. All	abnormal results are	reviewed and confirmed microscopically.
Absolute Neutrophil count (EDTA Blood)	5.44	10^3 / μΙ	1.5 - 6.6
Absolute Lymphocyte Count (EDTA Blood)	1.79	10^3 / μl	1.5 - 3.5
Absolute Eosinophil Count (AEC) (EDTA Blood)	0.08	10^3 / μl	0.04 - 0.44
Absolute Monocyte Count (EDTA Blood)	0.35	10^3 / μl	< 1.0
Absolute Basophil count (EDTA Blood)	0.05	10^3 / μl	< 0.2
Platelet Count (EDTA Blood)	171	10^3 / μl	150 - 450
MPV (EDTA Blood)	12.8	fL	8.0 - 13.3
PCT (EDTA Blood/Automated Blood cell Counter)	0.22	%	0.18 - 0.28
ESR (Erythrocyte Sedimentation Rate)	34	mm/hr	< 20





 PID No.
 : MED110806472
 Register On
 : 24/01/2023 8:41 AM

 SID No.
 : 423004656
 Collection On
 : 24/01/2023 9:18 AM

**Printed On** 

Type : OP

Ref. Dr : MediWheel



Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
<b>BIOCHEMISTRY</b>			
Liver Function Test			
Bilirubin(Total) (Serum/DCA with ATCS)	0.30	mg/dL	0.1 - 1.2
Bilirubin(Direct) (Serum/Diazotized Sulfanilic Acid)	0.13	mg/dL	0.0 - 0.3
Bilirubin(Indirect) (Serum/Derived)	0.17	mg/dL	0.1 - 1.0
SGOT/AST (Aspartate Aminotransferase) (Serum/ <i>Modified IFCC</i> )	27.54	U/L	5 - 40
SGPT/ALT (Alanine Aminotransferase) (Serum/Modified IFCC)	26.67	U/L	5 - 41
GGT(Gamma Glutamyl Transpeptidase) (Serum/IFCC / Kinetic)	23.21	U/L	< 38
Alkaline Phosphatase (SAP) (Serum/Modified IFCC)	118.2	U/L	42 - 98
Total Protein (Serum/Biuret)	7.18	gm/dl	6.0 - 8.0
Albumin (Serum/Bromocresol green)	4.95	gm/dl	3.5 - 5.2
Globulin (Serum/Derived)	2.23	gm/dL	2.3 - 3.6
A : G RATIO (Serum/Derived)	2.22		1.1 - 2.2

: 20/03/2023 2:59 PM





 PID No.
 : MED110806472
 Register On
 : 24/01/2023 8:41 AM

 SID No.
 : 423004656
 Collection On
 : 24/01/2023 9:18 AM

**Printed On** 

Type : OP

Ref. Dr : MediWheel

medall DIAGNOSTICS

Investigation	Observed <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
<u>Lipid Profile</u>			
Cholesterol Total (Serum/CHOD-PAP with ATCS)	185.70	mg/dL	Optimal: < 200 Borderline: 200 - 239 High Risk: >= 240
Triglycerides (Serum/GPO-PAP with ATCS)	112.20	mg/dL	Optimal: < 150 Borderline: 150 - 199 High: 200 - 499 Very High: >= 500

: 20/03/2023 2:59 PM

**INTERPRETATION:** The reference ranges are based on fasting condition. Triglyceride levels change drastically in response to food, increasing as much as 5 to 10 times the fasting levels, just a few hours after eating. Fasting triglyceride levels show considerable diurnal variation too. There is evidence recommending triglycerides estimation in non-fasting condition for evaluating the risk of heart disease and screening for metabolic syndrome, as non-fasting sample is more representative of the `usual\_circulating level of triglycerides during most part of the day.

HDL Cholesterol (Serum/Immunoinhibition)	41.77	mg/dL	Optimal(Negative Risk Factor): >= 60 Borderline: 50 - 59 High Risk: < 50
LDL Cholesterol (Serum/Calculated)	121.5	mg/dL	Optimal: < 100 Above Optimal: 100 - 129 Borderline: 130 - 159 High: 160 - 189 Very High: >= 190
VLDL Cholesterol (Serum/Calculated)	22.4	mg/dL	< 30
Non HDL Cholesterol (Serum/Calculated)	143.9	mg/dL	Optimal: < 130 Above Optimal: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very High: >= 220

**INTERPRETATION:** 1. Non-HDL Cholesterol is now proven to be a better cardiovascular risk marker than LDL Cholesterol. 2. It is the sum of all potentially atherogenic proteins including LDL, IDL, VLDL and chylomicrons and it is the "new bad cholesterol" and is a co-primary target for cholesterol lowering therapy.





**APPROVED BY** 

PID No. : MED110806472 Register On : 24/01/2023 8:41 AM

: 423004656 SID No. **Collection On** : 24/01/2023 9:18 AM

Age / Sex : 43 Year(s) / Female Report On : 24/01/2023 4:53 PM Type : OP

Ref. Dr : MediWheel

: 20/03/2023 2:59 PM **Printed On** 



Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Total Cholesterol/HDL Cholesterol Ratio (Serum/Calculated)	4.4		Optimal: < 3.3 Low Risk: 3.4 - 4.4 Average Risk: 4.5 - 7.1 Moderate Risk: 7.2 - 11.0 High Risk: > 11.0
Triglyceride/HDL Cholesterol Ratio (TG/HDL) (Serum/Calculated)	2.7		Optimal: < 2.5 Mild to moderate risk: 2.5 - 5.0 High Risk: > 5.0
LDL/HDL Cholesterol Ratio (Serum/Calculated)	2.9		Optimal: 0.5 - 3.0 Borderline: 3.1 - 6.0 High Risk: > 6.0





**APPROVED BY** 

**Printed On** 

Type : OP

Ref. Dr : MediWheel



<u>Investigation</u>	<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Glycosylated Haemoglobin (HbA1c)			
HbA1C (Whole Blood/ <i>HPLC</i> )	6.1	%	Normal: 4.5 - 5.6 Prediabetes: 5.7 - 6.4

: 20/03/2023 2:59 PM

INTERPRETATION: If Diabetes - Good control: 6.1 - 7.0 %, Fair control: 7.1 - 8.0 %, Poor control >= 8.1 %

Estimated Average Glucose 128.37 mg/dL

(Whole Blood)

### **INTERPRETATION: Comments**

HbA1c provides an index of Average Blood Glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

Conditions that prolong RBC life span like Iron deficiency anemia, Vitamin B12 & Folate deficiency,

hypertriglyceridemia, hyperbilirubinemia, Drugs, Alcohol, Lead Poisoning, Asplenia can give falsely elevated HbAlC values.

Conditions that shorten RBC survival like acute or chronic blood loss, hemolytic anemia, Hemoglobinopathies, Splenomegaly, Vitamin E ingestion, Pregnancy, End stage Renal disease can cause falsely low HbAlc.





Diabetic:  $\geq$  6.5

APPROVED BY

**Printed On** 

Type : OP

Ref. Dr : MediWheel



<u>Investigation</u>	<u>Observed</u>	<u>Unit</u>	<u>Biological</u>
	Value		Reference Interval

: 20/03/2023 2:59 PM

# **IMMUNOASSAY**

### THYROID PROFILE / TFT

T3 (Triiodothyronine) - Total 1.07 ng/ml 0.7 - 2.04

(Serum/ECLIA)

### INTERPRETATION:

#### **Comment:**

Total T3 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T3 is recommended as it is Metabolically active.

T4 (Tyroxine) - Total 7.76  $\mu g/dl$  4.2 - 12.0

(Serum/ECLIA)

### INTERPRETATION:

### **Comment:**

Total T4 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T4 is recommended as it is Metabolically active.

TSH (Thyroid Stimulating Hormone) 9.92 µIU/mL 0.35 - 5.50

(Serum/ECLIA)

### INTERPRETATION:

Reference range for cord blood - upto 20

1 st trimester: 0.1-2.5 2 nd trimester 0.2-3.0 3 rd trimester : 0.3-3.0

(Indian Thyroid Society Guidelines)

### Comment:

- 1.TSH reference range during pregnancy depends on Iodine intake, TPO status, Serum HCG concentration, race, Ethnicity and BMI.
- 2.TSH Levels are subject to circadian variation, reaching peak levels between 2-4am and at a minimum between 6-10PM. The variation can be of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.
- 3. Values&amplt,0.03 µIU/mL need to be clinically correlated due to presence of rare TSH variant in some individuals.





**APPROVED BY** 

Page 7 of 11

PID No. : MED110806472 Register On : 24/01/2023 8:41 AM SID No.

: 423004656 Collection On : 24/01/2023 9:18 AM

**Printed On** 

Age / Sex : 43 Year(s) / Female Report On : 24/01/2023 4:53 PM **Type** : OP

Ref. Dr : MediWheel



<u>Investigation</u>	<u>Observed</u> <u>U</u>	<u>nit</u> <u>Biological</u>
-	Value	Reference Interval

: 20/03/2023 2:59 PM

# **CLINICAL PATHOLOGY**

### PHYSICAL EXAMINATION (URINE COMPLETE)

Colour Pale Yellow Yellow to Amber

(Urine)

Clear Clear Appearance

(Urine)

Volume(CLU) 20

(Urine)

# CHEMICAL EXAMINATION (URINE

# **COMPLETE**)

рН 6.0 4.5 - 8.0

(Urine)

Specific Gravity 1.003 1.002 - 1.035

(Urine)

Negative Negative Ketone

(Urine)

Normal Normal Urobilinogen

(Urine)

Negative Negative Blood

(Urine)

Negative Negative **Nitrite** 

(Urine)

Negative Bilirubin Negative

(Urine)

Protein Negative Negative

(Urine)

Negative Negative Glucose

(Urine/GOD - POD)





PID No. : MED110806472

SID No.

: 423004656

Age / Sex : 43 Year(s) / Female

Type : OP

Ref. Dr : MediWheel Register On : 24/01/2023 8:41 AM

Collection On : 24/01/2023 9:18 AM

Report On : 24/01/2023 4:53 PM

**Printed On** : 20/03/2023 2:59 PM



Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>	
Leukocytes(CP) (Urine)	Positive(+)		Negative	
MICROSCOPIC EXAMINATION (URINE COMPLETE)				
Pus Cells (Urine)	2-5	/hpf	NIL	
Epithelial Cells (Urine)	1-3	/hpf	NIL	
RBCs (Urine)	NIL	/HPF	NIL	
Others (Urine)	NIL			
INTERPRETATION: Note: Done with Automated Urine Analyser & Automated urine sedimentation analyser. All abnormal reports are				

reviewed and confirmed microscopically.

/hpf NIL Casts NIL

(Urine)

Crystals NIL /hpf NIL

(Urine)





Age / Sex : 43 Year(s) / Female

**PID No.** : MED110806472

. IVILD I 10000-

**SID No.** : 423004656

Type : OP

Ref. Dr : MediWheel

Register On : 24/01/2023 8:41 AM

Collection On : 24/01/2023 9:18 AM

**Report On** : 24/01/2023 4:53 PM

Printed On : 20/03/2023 2:59 PM

medall DIAGNOSTICS

InvestigationObservedUnitBiologicalValueReference Interval

**IMMUNOHAEMATOLOGY** 

BLOOD GROUPING AND Rh TYPING

(EDTA Blood/Agglutination)

'B' 'Positive'





**PID No.** : MED110806472

SID No. : 423004656

. 120001000

Age / Sex : 43 Year(s) / Female

Type : OP

Ref. Dr : MediWheel

Register On : 24/01/2023 8:41 AM

Collection On : 24/01/2023 9:18 AM

**Report On** : 24/01/2023 4:53 PM

Printed On : 20/03/2023 2:59 PM



Investigation	Observed <u>Value</u>	<u>Unit</u>	<u>Biological</u> Reference Interval
<b>BIOCHEMISTRY</b>			
BUN / Creatinine Ratio	11.23		6.0 - 22.0
Glucose Fasting (FBS) (Plasma - F/GOD-PAP)	109.34	mg/dL	Normal: < 100 Pre Diabetic: 100 - 125 Diabetic: >= 126

**INTERPRETATION:** Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level.

Glucose, Fasting (Urine) Negative (Urine - F/GOD - POD) Negative  $Glucose \ Postprandial \ (PPBS)$  76.89 mg/dL 70 - 140

(Plasma - PP/GOD-PAP)

### INTERPRETATION:

Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level. Fasting blood glucose level may be higher than Postprandial glucose, because of physiological surge in Postprandial Insulin secretion, Insulin resistance, Exercise or Stress, Dawn Phenomenon, Somogyi Phenomenon, Anti- diabetic medication during treatment for Diabetes.

Blood Urea Nitrogen (BUN)	7.3	mg/dL	7.0 - 21
(Serum/ <i>Urease UV / derived</i> )			
Creatinine	0.65	mg/dL	0.6 - 1.1
(Serum/Modified Jaffe)			

**INTERPRETATION:** Elevated Creatinine values are encountered in increased muscle mass, severe dehydration, Pre-eclampsia, increased ingestion of cooked meat, consuming Protein/ Creatine supplements, Diabetic Ketoacidosis, prolonged fasting, renal dysfunction and drugs such as cefoxitin ,cefazolin, ACE inhibitors ,angiotensin II receptor antagonists,N-acetylcyteine , chemotherapeutic agent such as flucytosine etc.

Uric Acid 5.62 mg/dL 2.6 - 6.0

(Serum/Enzymatic)





APPROVED BY

-- End of Report --



Name	Ms.USHA YADAV	ID	MED110806472
Age & Gender	43/FEMALE	Visit Date	24/01/2023
Ref Doctor Name	MediWheel		

# X-ray mammogram (mediolateral oblique and craniocaudal views) followed by Sonomammography was performed.

# MAMMOGRAPHY OF BOTH BREASTS

Both breasts show symmetrical fibro fatty tissue.

No evidence of focal soft tissue lesion.

No evidence of cluster micro calcification.

Subcutaneous fat deposition is within normal limits.

## SONOMAMMOGRAPHY OF BOTH BREASTS

Both breasts show normal echopattern.

No evidence of focal solid / cystic areas in either breast.

No evidence of ductal dilatation.

Few lymphnodes with maintained fatty hilum are noted in both axillae.

### **IMPRESSION:**

> NO SIGNIFICANT ABNORMALITY.

ASSESSMENT: BI-RADS CATEGORY -1

# DR. APARNA CONSULTANT RADIOLOGIST

A/da

### **BI-RADS CLASSIFICATION**

**CATEGORY** RESULT

O Assessment incomplete. Need additional imaging evaluation REPORT DISCLAIMER

- 1. This is only a radiologincal imperssion. Like other investigations, radiological investication also have limitation. Therefore radiologincal reports should be interpreted in correlation with clinical and pathological findings.
- 2. The results reported here in are subject to interpretation by qualified medical professionals only.
- 3. Customer identities are accepted provided by the customer or their representative.
- 4.information about the customer's condition at the time of sample collection such as fasting, food consumption, medication, etc are accepted as provided by the customer or representative and shall not be investigated for its truthfulness.
- 5.If any specimen/sample is received from any others laboratory/hospital,its is presumed that the sample belongs to the patient identified or named.
- 6.Test results should be interpreted in context of clinical and other findings if any. In case of any clarification /doubt, the refrering doctor/patient can contact the respective section head of the laboratory.
- 7.Results of the test are influenced by the various factors such as sensitivity, specificity of the procedures of the tests, quality of the samples and drug interactions etc.,
- 8.If the test results are found not to be correlating clinically can contact the lab in charge for clarification or retesting where practicable within 24 hours from the time of issue of results.
- 9.Liability is limited to the extend of amount billed.
- O.Reports are subject to interpretation in their entirety.partial or selective interpretation may lead to false oninion
- $11. Disputes, if any \ , with regard to the report findings are subject to the exclusive jurisdiction of the competent courts chennai only. \\$



Name	Ms.USHA YADAV	ID	MED110806472
Age & Gender	43/FEMALE	Visit Date	24/01/2023
Ref Doctor Name	MediWheel		

1	Negative. Routine mammogram in 1 year recommended.	
2	Benign finding. Routine mammogram in 1 year recommended.	
3	Probably benign finding. Short interval follow-up suggested.	
4	Suspicious. Biopsy should be considered.	
5	Highly suggestive of malignancy. Appropriate action should be taken.	

#### REPORT DISCLAIMER

- 1. This is only a radiologincal imperssion. Like other investigations, radiological investication also have limitation. Therefore radiologincal reports should be interpreted in correlation with clinical and pathological findings.
- 2. The results reported here in are subject to interpretation by qualified medical professionals only.
- 3.Customer identities are accepted provided by the customer or their representative.
- 4.information about the customer's condition at the time of sample collection such as fasting, food consumption, medication, etc are accepted as provided by the customer or representative and shall not be investigated for its truthfulness.
- 5.If any specimen/sample is received from any others laboratory/hospital,its is presumed that the sample belongs to the patient identified or named.
- 6.Test results should be interpreted in context of clinical and other findings if any.In case of any clarification /doubt , the refrering doctor/patient can contact the respective section head of the laboratory.
- 7.Results of the test are influenced by the various factors such as sensitivity, specificity of the procedures of the tests, quality of the samples and drug interactions etc.,
- 8.If the test results are found not to be correlating clinically can contact the lab in charge for clarification or retesting where practicable within 24 hours from the time of issue of results.
- 9.Liability is limited to the extend of amount billed.
- 10.Reports are subject to interpretation in their entirety.partial or selective interpretation may lead to false opinion.
- $11. Disputes, if any \ , with regard to the report findings are subject to the exclusive jurisdiction of the competent courts chennai only. \\$